Bristol-Myers Squibb (BMY - Get Report) was initiated with a sell rating at Societe Generale. $48 price target. Earnings estimates are also below Street consensus, given lower expectations for its Opdivo cancer treatment, Societe said.
Chemtura (CHMT) was upgraded to buy at TheStreet Ratings.
Coach (COH) was upgraded to outperform from market perform at William Blair. A recent survey suggests a potential inflection point in the business, William Blair said.
Ollie's Bargain (OLLI - Get Report) was upgraded to overweight from neutral at Piper Jaffray. $28 price target. The company continues to execute and has attractive long-term growth potential, Piper said.